Close Menu

Harvard

Vista has secured rights to the nanowire technology from Harvard and previous spinout Nanosys, which has, for the time being, eschewed biomedical applications for the tech in favor of nearer-term commercial opportunities.

Pairings: Feb 25, 2009

Premium

Elias Zerhouni, Joshua LaBaer

The Quest For Function

Premium

Small RNA research continues to heat up as scientists deploy experimental and new computational tools to elucidate function. Plus, a peek at new findings in snoRNAs and moRs.

Already, the promise of synthetic biology is being realized as this level of engineering is brought into drug development. GT looks into synthetic biology drugs in the pipeline and where this field is heading.

Not That Kind of ESP

Premium

Harvard researchers have built a computational tool that they believe could help get more protein biomarkers into clinical use.

Mark Schmeizl, David Sneider, David Cox, Joshua LaBaer

The $3 million Stem Cell Commercialization Facility will open in June within 2,508 square feet of TechOne, the 100,000-square-foot first building of up to three that are planned to comprise the tech park, called TechTown.

David Silver, Jan Bouten

Elias Zerhouni has joined the Gates Foundation, Aushon Biosystems has named a new VP of North American Sales, Joshua LaBaer heads West to Arizona State University, and more.

Vista will use the technology to develop real-time monitoring of biomarkers associated with organ and tissue damage.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.